Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00091637
Status:
COMPLETED
Last Update Posted:
2023-11-18
First Post:
2004-09-14
Brief Title:
Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction APEX-AMI
Sponsor:
Procter and Gamble
Organization:
Procter and Gamble
Study Overview
Official Title:
APEX-AMI - Pexelizumab in Conjunction With Angioplasty
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention PCI the bodys own inflammatory system involving the complement cascade may be harmful This study will test the safety and efficacy of a novel complement inhibitor pexelizumab to reduce mortality at 30 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None